Viikki M, Pukkala E, Hakama M
University of Tampere School of Public Health, Finland.
Obstet Gynecol. 1998 Aug;92(2):269-73. doi: 10.1016/s0029-7844(98)80070-7.
To estimate the subsequent incidence of cancers of endometrium, ovary, vulva, and vagina among women with positive cytology at screening for cervical cancer followed by negative histology.
This was a longitudinal cohort study involving women attending the organized mass screening in Finland from 1971-1990 with class II, III, IV, or V cytology followed by negative histologic confirmation, and a sample of 42,844 women attending the organized mass screening in Finland in 1971-1976 with cytologic class I smears without any gynecologic symptoms or infections. Follow-up on the women to the end of 1994 for subsequent cancers was maintained by linkage to the national cancer registry. Standardized incidence ratios with 95% confidence intervals (CI), with rates for all of Finland as reference, were estimated.
The standardized incidence ratios after negative class I smears of all the cancers studied were between 0.9 and 1.0. Ovarian cancer was not associated with positive cervical cytology. After positive class III-V cytology, the standardized incidence ratio of endometrial carcinoma was 1.6 (CI 1.0, 2.2) and that of vulvar carcinoma was 5.8 (CI 2.3, 12). The standardized incidence ratios of vaginal cancer after class II and III-V cytological smear were 2.7 (CI 1.7, 4.1) and 16.4 (CI 7.1, 32), respectively. The relative risks of all the cancers studied were greatest during the first year of follow-up and persisted for more than 5 years for vulvar and vaginal cancers.
Although the Papanicolaou smear is poor in detecting cancers other than cervical, in clinical practice, the possibility of other gynecologic cancer has to be considered in surveillance after positive cervical cytology is followed by negative histology.
评估宫颈癌筛查细胞学检查阳性但组织学检查阴性的女性中子宫内膜癌、卵巢癌、外阴癌和阴道癌的后续发病率。
这是一项纵向队列研究,纳入了1971年至1990年在芬兰参加有组织大规模筛查且细胞学检查为II、III、IV或V级随后组织学检查阴性的女性,以及1971年至1976年在芬兰参加有组织大规模筛查且细胞学涂片为I级且无任何妇科症状或感染的42844名女性样本。通过与国家癌症登记处联动对这些女性进行随访,直至1994年底以了解后续癌症情况。估计了以芬兰所有人群发病率为参考的标准化发病率比及95%置信区间(CI)。
所有研究癌症在I级涂片阴性后的标准化发病率比在0.9至1.0之间。卵巢癌与宫颈细胞学检查阳性无关。III - V级细胞学检查阳性后,子宫内膜癌的标准化发病率比为1.6(CI 1.0,2.2),外阴癌为5.8(CI 2.3,12)。II级和III - V级细胞学涂片后阴道癌的标准化发病率比分别为2.7(CI 1.7,4.1)和16.4(CI 7.1,32)。所有研究癌症的相对风险在随访的第一年最大,外阴癌和阴道癌的相对风险持续超过5年。
尽管巴氏涂片在检测宫颈癌以外的癌症方面效果不佳,但在临床实践中,对于宫颈细胞学检查阳性随后组织学检查阴性的情况进行监测时,必须考虑其他妇科癌症的可能性。